> top > projects > Inflammaging > docs > PubMed:35445052 > annotations
Inflammaging  

PubMed:35445052 JSONTXT 6 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T1 0-162 Sentence denotes Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome:
T1 0-162 Sentence denotes Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome:
T2 163-205 Sentence denotes Protocol of a Randomized Controlled Trial.
T2 163-205 Sentence denotes Protocol of a Randomized Controlled Trial.
T3 206-217 Sentence denotes Background:
T3 206-217 Sentence denotes Background:
T4 218-380 Sentence denotes Patients with chronic kidney disease (CKD) are at high risk of developing heart failure and anemia, which is defined as type 4 cardiorenal-anemia syndrome (CRAS).
T4 218-380 Sentence denotes Patients with chronic kidney disease (CKD) are at high risk of developing heart failure and anemia, which is defined as type 4 cardiorenal-anemia syndrome (CRAS).
T5 381-491 Sentence denotes CRAS aggravates the deterioration of both kidney and heart function, ultimately resulting in a high mortality.
T5 381-491 Sentence denotes CRAS aggravates the deterioration of both kidney and heart function, ultimately resulting in a high mortality.
T6 492-589 Sentence denotes This study aims to examine the efficacy and safety of roxadustat in the treatment of type 4 CRAS.
T6 492-589 Sentence denotes This study aims to examine the efficacy and safety of roxadustat in the treatment of type 4 CRAS.
T7 590-609 Sentence denotes Methods and Design:
T7 590-609 Sentence denotes Methods and Design:
T8 610-679 Sentence denotes This study is designed as a randomized, open-label, controlled trial.
T8 610-679 Sentence denotes This study is designed as a randomized, open-label, controlled trial.
T9 680-813 Sentence denotes A total of 68 patients diagnosed with type 4 CRAS will be randomly divided into roxadustat group and erythropoietin with a 1:1 ratio.
T9 680-813 Sentence denotes A total of 68 patients diagnosed with type 4 CRAS will be randomly divided into roxadustat group and erythropoietin with a 1:1 ratio.
T10 814-1106 Sentence denotes Participants in the roxadustat group will receive roxadustat with an initial dose of 70 or 100 mg three times a week, and participants in the erythropoietin group will receive subcutaneous injection of erythropoietin for 24 weeks, to maintain a hemoglobin ranging from 100 to 120 g per liter.
T10 814-1106 Sentence denotes Participants in the roxadustat group will receive roxadustat with an initial dose of 70 or 100 mg three times a week, and participants in the erythropoietin group will receive subcutaneous injection of erythropoietin for 24 weeks, to maintain a hemoglobin ranging from 100 to 120 g per liter.
T11 1107-1273 Sentence denotes The primary outcome is the change in heart function, including brain natriuretic peptide (BNP), 6-min walk test (6-WT), and left ventricular ejection fraction (LVEF).
T11 1107-1273 Sentence denotes The primary outcome is the change in heart function, including brain natriuretic peptide (BNP), 6-min walk test (6-WT), and left ventricular ejection fraction (LVEF).
T12 1274-1711 Sentence denotes Secondary outcomes to be assessed include death, cardiovascular events, hospitalization regarding heart failure, Minnesota Heart Failure Quality of life scale (MLHFQ) score, New York Heart Association (NYHA) cardiac function grade, echocardiographic parameters including left ventricular diastolic diameter and volume (LVDD and LVDV) and ventricular mass (LVM), anemia related parameters, inflammatory parameters, and safety assessments.
T12 1274-1711 Sentence denotes Secondary outcomes to be assessed include death, cardiovascular events, hospitalization regarding heart failure, Minnesota Heart Failure Quality of life scale (MLHFQ) score, New York Heart Association (NYHA) cardiac function grade, echocardiographic parameters including left ventricular diastolic diameter and volume (LVDD and LVDV) and ventricular mass (LVM), anemia related parameters, inflammatory parameters, and safety assessments.
T13 1712-1723 Sentence denotes Conclusion:
T13 1712-1723 Sentence denotes Conclusion:
T14 1724-1817 Sentence denotes The findings of this study will provide potential evidence for roxadustat in CRAS management.
T14 1724-1817 Sentence denotes The findings of this study will provide potential evidence for roxadustat in CRAS management.
T15 1818-1837 Sentence denotes Trial Registration:
T15 1818-1837 Sentence denotes Trial Registration:
T16 1838-1874 Sentence denotes Chinese Clinical Trial Registry, ID:
T16 1838-1874 Sentence denotes Chinese Clinical Trial Registry, ID:
T17 1875-1892 Sentence denotes ChiCTR2100050031.
T17 1875-1892 Sentence denotes ChiCTR2100050031.
T18 1893-1922 Sentence denotes Registered on 16 August 2021.
T18 1893-1922 Sentence denotes Registered on 16 August 2021.